Bans on gender-affirming care for minors are now in effect in 27 states, and after the Supreme Court’s June 2025 decision in United States v. Skrmetti, constitutional challenges to those laws face very long odds. The bans typically prohibit puberty blockers, hormone therapy, and surgery when prescribed to treat gender dysphoria in anyone under 18, and a January 2025 federal executive order pushes the cutoff to under 19 for anything touching federal funding. The consequences reach further than the exam room: a provider can lose a license or face felony charges, a family can face a child protective services investigation, and insurance coverage through Medicaid, TRICARE, or federal employee plans is being pulled back.
What the Bans Actually Restrict
Three categories of medical treatment are covered. Puberty blockers, meaning GnRH agonists that pause the hormonal signals of puberty. Cross-sex hormones, meaning testosterone or estrogen prescribed to develop physical characteristics aligned with a patient’s gender identity. And surgery, including chest procedures and genital reconstruction.
A detail that trips people up: the same medications remain legal for other diagnoses. Puberty blockers prescribed for precocious puberty are fine. Hormones prescribed for other endocrine conditions are fine. The prohibition attaches to the purpose of the prescription, which is why pharmacies and insurers increasingly verify the diagnosis code before filling or paying.
Most laws do not restrict social transition steps like a change of name or clothing. The legal focus is on medical and surgical care. Age cutoffs and carve-outs vary by state, and the federal executive order uses 19 rather than 18.1The White House. Protecting Children from Chemical and Surgical Mutilation
If Your Child Is Already in Treatment
Several states include grandfather or wind-down clauses that let minors who started puberty blockers or hormone therapy before the ban continue for some period. The terms vary sharply. Some states permit ongoing prescriptions indefinitely for patients who began before a fixed date. Others require the patient to taper off entirely by a deadline. Missing that deadline can expose both the family and the prescribing physician to the same penalties as any other violation.
A minor who started blockers six months before a ban may keep access, while a peer diagnosed a week after the law took effect gets none. That gap is what has driven families to travel to states where the care is still legal, and it is what shield laws (below) are meant to address.
What Providers Face
Penalties for physicians stack across three channels, and states increasingly use all three at once.
License Discipline
Most state statutes authorize the medical board to revoke or suspend a provider’s license for delivering prohibited care. The language usually says the board “may” revoke, which leaves discretion, but a board investigation is career-threatening in itself. Discipline in one state routinely triggers reciprocal review in every other state where the provider is licensed. For pediatric endocrinologists and adolescent medicine specialists, that can effectively end a practice.
Extended Civil Liability
Several states have created special causes of action letting former patients sue years or decades after treatment. In enacted state laws, the filing window runs from 12 years to 30 years after the patient turns 18. A pending federal bill would set 25 years. Ordinary medical malpractice claims must usually be filed within two to four years, so the exposure gap is enormous. Damages can include the cost of reversal procedures, emotional distress, and lost fertility.
Criminal Prosecution
Some states make providing this care a felony. Alabama classifies it as a Class C felony carrying up to ten years in prison. At the federal level, H.R. 3492, the Protect Children’s Innocence Act, would impose up to ten years per violation. That bill passed the House 216–211 in late 2025 and was referred to the Senate Judiciary Committee, where it remained as of early 2026.2Congress.gov. HR 3492 – 119th Congress (2025-2026) Protect Children’s Innocence Act Prosecutions have been rare, but the threat has already reshaped institutional behavior: hospitals and clinics have pulled back from offering the care rather than expose staff to felony charges.
What Families Face
Insurance and Coverage Loss
Both state bans and the federal executive order use financial levers alongside the medical prohibition. Medicaid reimbursement for transition-related care for minors is being blocked at the state level and pushed against at the federal level, which puts the treatment out of reach for the families least able to pay out of pocket. State employee health plans in many banning states have been directed to exclude the care. The federal executive order tells the Office of Personnel Management to exclude these services from Federal Employee Health Benefits and Postal Service Health Benefits plans starting in the 2026 plan year, and to remove coverage from TRICARE.1The White House. Protecting Children from Chemical and Surgical Mutilation
Section 1557 of the Affordable Care Act, which prohibits sex discrimination in federally funded healthcare, was previously interpreted by HHS to cover gender identity. That interpretation has been rescinded, and a 2024 rule that would have codified it is blocked by a nationwide preliminary injunction. Patients in states without their own nondiscrimination protections have limited recourse if a provider or insurer denies care based on gender identity.
Child Abuse Investigations and Custody
Some state laws redefine parental support for a child’s gender-affirming care as child abuse or neglect. That reclassification pulls the case into the child protective services system. Teachers, physicians, and social workers become mandatory reporters. A referral can lead to a home investigation, temporary removal, and court proceedings.
Following your child’s medical team’s advice can therefore constitute what your state defines as abuse, even though the American Academy of Pediatrics, the American Medical Association, and the American College of Obstetricians and Gynecologists all support access to this care for transgender adolescents. States have opened investigations on this basis; some enforcement has been blocked in court, but the exposure is real.
In custody disputes between separated parents, one parent’s support for a child’s transition can become a factor the court weighs. If the other parent objects, they can argue in a banning state that supporting the care is harmful under the state’s abuse standards. Family courts in those states may restrict the affirming parent’s custody or add conditions to visitation.
Traveling for Care and the Limits of Shield Laws
Fourteen states and the District of Columbia have enacted shield laws to protect patients, families, and providers of gender-affirming care that is legal where delivered. Three additional states have executive orders with similar protections.
Shield laws generally block state law enforcement from cooperating with out-of-state investigations tied to this care, prohibit state courts from honoring out-of-state subpoenas for related medical records or provider testimony, and refuse extradition of people charged under another state’s ban when the person was not physically present in the charging state at the time of the alleged offense.
The protection is real but bounded. A family from a banning state that travels to a shield state for a hormone therapy appointment is covered while there. The shield state will not turn over records or the provider. But shield laws do not stop the home state from investigating once the family returns, and they do not stop a home-state custody action. The federal executive order also directs the Attorney General to look at states that facilitate access to this care and to consider using the Parental Kidnapping Prevention Act against them, which sets up a federal-versus-state conflict that has not yet been resolved in court.1The White House. Protecting Children from Chemical and Surgical Mutilation
Why Skrmetti Matters for Anyone Hoping the Courts Will Undo These Laws
On June 18, 2025, the Supreme Court decided United States v. Skrmetti and upheld Tennessee’s ban on gender-affirming care for minors.3Supreme Court of the United States. United States v Skrmetti, No 23-477 The fight was over which constitutional standard applies. The federal government argued the ban should face heightened scrutiny because it disproportionately affects transgender minors. The Court disagreed, holding that the law classifies based on age and medical purpose, not on transgender status, because the same drugs remain available for other diagnoses. That framing triggered rational basis review, the most deferential test in constitutional law.
A law survives rational basis if any conceivable justification supports it. Tennessee pointed to concerns about irreversible sterility, limited long-term safety data, and minors’ capacity to weigh life-altering consequences. The Court found those reasons enough and said questions about medical uncertainty belong to legislatures, not judges. Future equal protection challenges to similar state bans face the same steep climb.3Supreme Court of the United States. United States v Skrmetti, No 23-477
Restrictions Are Moving Past Age 18
The wave of enacted bans focuses on minors, but the age line is drifting. Several states have considered banning gender-affirming care for anyone under 26. Multiple states already prohibit public funds from covering transition-related healthcare at any age, which reaches anyone on Medicaid, in state employment, or incarcerated in those states. The federal executive order’s use of “under 19” already extends federal funding restrictions past the typical age of majority.1The White House. Protecting Children from Chemical and Surgical Mutilation With Skrmetti‘s deferential standard now the baseline, legislatures have more room to try broader bans.
The Gap Between Medical Consensus and the Law
The major U.S. medical associations oppose these bans. The American Academy of Pediatrics has reaffirmed its policy supporting gender-affirming care and authorized a systematic evidence review. The American Medical Association, the American College of Obstetricians and Gynecologists, and the World Health Organization have taken similar positions, arguing that treatment decisions should stay with patients, families, and physicians based on individualized clinical judgment.
State legislatures have justified their bans with legislative findings about medical uncertainty and regret rates, and the Supreme Court in Skrmetti held that legislatures are entitled to make those judgments even where professional medical bodies disagree.3Supreme Court of the United States. United States v Skrmetti, No 23-477 For a family navigating this in a banning state, that is the practical bind: your child’s doctor’s recommendation and your state’s law can point in opposite directions, and the courts are unlikely to resolve the conflict in your favor.